Also called Aquipta and made by AbbVie, NICE has recommended atogepant as an option for preventing chronic and episodic migraines in adults who have had at least 4 migraine days per month and where at least 3 previous preventive treatments have failed.
Affecting around 4.5 million people in England, migraines can have a significant impact on a person’s daily life, as well as placing a heavy burden on the NHS and the wider economy.
Chronic migraine is where a person has at least 15 headache days a month, with at least 8 of those having features of migraine…
